Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
[5.8k more just happened at $0.4850 [added shares today, last week, more to come]
Arh Dan
@Arhdan9
1m
$NWBO $XBI $NVCR
Lucky to add a tiny of 5.5k shares of $NWBO so far today. More to come. $NWBO market cap will pass that of $NVCR this year, going much higher there after. We all know what is going to come after super quietness [on the basis of positive data, more awareness, plenty of time to submit marketing applications to multiple RAs).
In addition to last week's purchase of 38k shares at average around $0.49 per share, hardly making a splash in repeatedly peaked 7-figure holding in terms of average share price.
Go big or go home.
Good for you to have accumulated a sizable of shares. I am in the same boat, and have dampened my expectation for a paying out day soon since we didn't see one on datalock, positive data presentation at NYAS, and JAMA Oncology publication as we had so expected if the market behaves normally.
We are in a battle with the manipulators, but my conviction is we will win at due time which I am personally afforded to well after regulatory approvals --- with revenue coming in and increasing steeply q after q. That will be my pay out day. What I can do is to continually accumulate at any possible time if the price is low.
Of course I don't rule out the manipulators would capitulate well before my tolerate day, which is very likely. It's just I have set my day well beyond, at least for my sanity so I would see any day with low price as a day of accumulation, not a day of frustration.
Good weekend to you too!
You have been here for years that you have summarize how Linda does things pretty well. So just forget about timing, instead focus on accumulating!
With NWBO, timing is the most stupid thing investors can/will do.
Anyone is prone to slip when talking too much. There is no standard for how long should it take for a company to prepare and submit an MAA or a BLA for regulatory approval, particularly considering most such applications deal wit one indication, not twos such as ours, ie, nGBM and rGBM.
It is also true this is not in the original design and it only becomes true when the trial unfolded. As a result, a well-thought out and careful preparation is warranted. I guess the company would like to supply ancillary material/data as much as possible in order to ascertain the positive outcomes. In this regard, starting "slow" may at the end expedites the approving process instead.
After all, the company has never give any specific guideline and only said it would happen this year.
My guess is we may see the news any day from now, but would not think it's out of bounds if it happens one month or so later.
Not bragging or else depending on one's perspective, I have continued adding shares which repeatedly peak for years, and will continue do so until I think it's enough at such depressed prices.
Keep the good work in the scientific ground my friend.
I have a feeling on the amended complaints due 10 April, besides spoofing, there will be violation of Rule 10b-5 under the Exchange Act for selling stock short and failing to deliver shares at the time of settlement with the purpose of driving down the security’s price. This manipulative activity, in general, would violate various securities laws. One obvious example would be trading on and shortly after 10 May 2022.
https://law.stackexchange.com/questions/70485/under-what-circumstances-are-market-makers-allowed-to-engage-in-naked-short-sel
"Rule 204 – Close-out Requirement. Rule 204 requires brokers and dealers that are participants of a registered clearing agency[8] to take action to close out failure to deliver positions. Closing out requires the broker or dealer to purchase or borrow securities of like kind and quantity. ... If a participant has a failure to deliver that the participant can demonstrate on its books and records resulted from a long sale, or that is attributable to bona fide market making activities, the participant must close out the failure to deliver by no later than the beginning of regular trading hours on the third consecutive settlement day following the settlement date, referred to as T+6. ... Rule 203(b)(3) of Regulation SHO requires that participants of a registered clearing agency must immediately purchase shares to close out failures to deliver in securities with large and persistent failures to deliver, referred to as “threshold securities,” if the failures to deliver persist for 13 consecutive settlement days
...
Selling stock short without having located stock for delivery at settlement. This activity would violate Regulation SHO, except for short sales by market makers engaged in bona fide market making. Market makers engaged in bona fide market making do not have to locate stock before selling short, because they need to be able to provide liquidity. However, market makers are not excepted from Regulation SHO’s close-out and pre-borrow requirements.
Selling stock short and failing to deliver shares at the time of settlement. Rule 204 requires firms that clear and settle trades to deliver securities to a registered clearing agency for clearance and settlement on a long or short sale in any equity security by the settlement date or to take action to close out failures to deliver by borrowing or purchasing securities of like kind and quantity ...
Selling stock short without having located stock for delivery at settlement and failing to deliver shares at the time of settlement. This activity may violate Regulation SHO’s locate and close-out requirements, as explained above. In addition, in fall 2008 the Commission adopted Rule 10b-21, referred to as the “naked” short selling antifraud rule. Those who deceive about their intention or ability to deliver securities in time for settlement are committing fraud, in violation of Rule 10b-21, when they fail to deliver securities by the settlement date.
Selling stock short and failing to deliver shares at the time of settlement with the purpose of driving down the security’s price. This manipulative activity, in general, would violate various securities laws, including Rule 10b-5 under the Exchange Act."
Saw the accused MMs have to use him/his tweet as cover for a penny or two price manipulation since his tweet.
For most pre-commercial biotech companies seeking FDA approval, manufacturing readiness is usually the last step to check by FDA before its making decision on whether to approve the underlining drug/biological product/vaccine, so in this sense June 2023 is more than achievable since UK MHRA has just checked the readiness item (module).
By the time when MAA is submitted, it's also possible MHRA has reviewed most, if not all contents of MAA, so it is certainly possible the approval may come earlier than a lot of folks would expect.
Regardless, it becomes easier by the days/months to hold and/or add more shares as we have done just that already for years, if not a decade.
Your frustration is warranted, but the window of frustration is quickly shrinking. I am a buyer, to be exact, have been a buyer with price in this depressed range, having averaged up with buys as high as $1.6s, and as low as low $0.4s with huge numbers on 10 May, as recently as yesterday at $0.57 and up.
I know I am going to be happier with each buy as day passes by.
As least the time to approval is quickly shrinking.
Was Dr. Bosch supposed to present not only P3 trial data, which is gorgeous with some added tidbits, but also MANUFACTURING? Where is MANUFACTURING part in the powerpoint?
MIA + imminent.
As said before, bought 18K shares at price ranging from $0.57-0.585. Loved this price as MMs have resorted to scare tactics baring no news.
Nobody knows when news comes.
After chasing bits up this morning, first set at $0.56, and then all the way up to $0.585, never got filled below $0.57 though, would take a break this morning.
Will be back this afternoon.
JAMA Oncology paper, increasingly bullish GBM sphere, increased retail investor base, cornered regulatory agencies failing to act fast and proactive, accused MMs on watch, expending patents and manufacturing, now we just need a trigger.
Under the current market circumstances, NWBO's loan with John Fife is reasonably good financing deal we can expect for. No dilution, reasonable cost with annualized rate around 17%.
Better than issuing enough C-shares at distressed price.
Better than toxic diluted financing, issuing shares and/or warrant.
Yes, there are always some people who don't like it.
As retail, I had chased the bits up, and still not got filled for my last bit for 3600 shares at $0.60 routed to CEDL on Friday.
Going to buy more coming Monday.
Annual interest rate for NWBO's $11 million loan with John Fife:
Quoted a poster who said, "I did this for a living for way too long."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171420045
His post I quote (within quotation marks):
"LOL wow Kab is that how you calculate interest? Just add them up?
From my post yesterday.
Distressed financing once again:
8% interest on loan
10% OID
10% "premium" added to 14 monthly installments
I've calculated a 25.2% effective annual rate on this loan."
Source post: https://investorshub.advfn.com/boards/replies.aspx?msg=171412867
Today in reply to this post: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171422379 which shows detailed month by month calculations indicating annual interest rate is about 17%, he says (I quote, within quotation marks):
" The only correction that I see is that the amount received = $9,904,500. If there's wordage in the loan that says $10M received please let me know.
I made an error in that I calculated the term at 21 months instead of 22. We are almost identical in total amount paid.
I also used compound interest in my calcuations.
Nice work!"
(source post: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171423758)
As of now, the post who makes living by doing this kind of things seems still to get it wrong with the amount received. The poster still believes it is $9,904,500 instead of $10M. LOL
Conclusion: aperture007 in his post has demonstrated with detailed month by month calculations how this loan will be charged and paid, and the annual interest rate is about 17%, not 25% or 39%.
The question is if any ones who want to invest in NWBO, particularly those who make living by doing this kind of things, how can they get such calculations awfully wrong? And why have they as experts got such thing, and to be accurate pretty much anything nwbo persistently wrong?
[another expert say the rate is 30%: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171422511]
bought a bunch again, even chased up bits. My last bit for 3600 at $0.60 (routed to cdel) have not got filled before market close.
cheer!
You are absolutely right on this. I think spoofing is just a bait for the 8 accused MMs and so far they seem to have been hooked up -- wrangling around desperately, because spoofing surely will be readily proved and the MMs will definitely pay for it.
But how munch is the next question. Because I am 100% sure they have been much deep in manipulation as you suggested, ie, naked shorting for years, they must pay unprecedented sums of money, in billion if not billions to settle, because they would not prefer discovery going forward, which will lead to exposure of their whole dirty laundry in the public eye, which will lead to criminal cases against them from multiple angles, including the government.
We will just have to wait for this to comes to fruition. Buy, add, and hold.
I don't pay much attention to anything such as Advent/CRL job posting, extremely upbeat management mood, or how much is the revenue from special program, or nobody knows the direction, or other peripherals (not that they are not signs), but this:
1) JAMA Oncology paper is good; 2) patent portfolio is expanding; 3) GBM sphere is exciting and expecting approval; 4) the day before loan is good (yes it could be better as bears so conveniently criticized); 5) to be determined, and of course 6) the recent price movement in tandem with the souring general market sentiment is negative. As a result, nwbo is once again a strong.
I don't know anyone else but I pretty much think I do know the direction moving forward (not a genius to know exact timing though): MIA, MAA/BLA, regulatory approvals one after another, all will come (partnership deals if materialized are just bonus).
We will beat the general market, not by 50%, but 1,000% in not a distant future (hi Linda).
Buy, add and hold.
There are always selling and buying which makes the market setting aside the manipulation just for now.
When prices were in teens there were sellers and buyers. I am one of those who bought in that range.
Yesterday's loan in and of itself is a good deal unless you count a good deal as interest free or free money. I understand some language such as the preparation for an application for market approval sounds stupid: how come Linda Powers has not done this? But we are investing in NWBO, we got know now how it behaves that only thing we should know is this: regardless of how slow Linda moves things, at end she has always got it done.
Bearing that in mind, regardless of time, days or months. MIA approval is coming, MAA/BLA is coming ...
We may not realize this is that moment once again as we didn't realize the moment when we bought shares around teens.
At least when we bought at teens, we didn't know the data would be positive. Now we know it is positive, and regulatory bodies get to approve it, if we can put the time stamp aside just for the sake of sanity.
Buy, add, hold, be happy!
Got more filled below $0.64, feel we will be green this afternoon as general market deepens into red. Yesterday's loan alone should increase price a bit, nothing to be worry about, Linda is a human being, she moves things as most of us do.
@Arhdan9
$NWBO $XBI #CitadelScandal
Simply report: added 36k shares between $0.65-0.64 so far this morning. said too much on the bright future of #DCVax in treating all kinds of cancers alone or in combination to substantially improve OS or cure cancers. Relax, take advantage, happy!
More to come this afternoon as I has bits set below $0.64.
[as I am typing, notice some get filled already]
Watch me buy 38k shares starting from 13pm. Guess which blocks are mine until 16pm.
these shares when done are just for fun, even my shares counts would again peak.
Linda take your path and pace and a break or two when needed, I like it.
Let nothing unchecked please.
Re lawsuit, re price, re nwbo:
Just a food for thought -- It may be a possibility for the MMs to intentionally maintain the price in this range $0.70s because if they let the price rise substantially, they may fear the motive for their spoofing action may be readily established, which Citadel has vehemently try to say otherwise, despite that it just doesn't matter spoofing is spoofing regardless price increase, decrease or not.
So in that case it should be easy to collect more evidences of other kinds of illegal MM transaction activities so they do face the possibility of being exposed with more illegal activities while trying to cover one illegal activity (spoofing).
Anyhow it seems the lawsuit will enter the next phase where there will be a rich discovery of some more serious illegal activities committed by MMs during the same period, including naked shorting if a rich out-of-court deal in the billion(s) is not reached. I guess the only thing that matter to them as of now is just delay this process at any cost.
So if with news, price doesn't increase duly, Mr. Black and our lawyers should have some rewarding and exciting field days.
NWBO at this time doesn't need any forms of pumping, or any stripes of pumpers, because the JAMA Oncology paper is the testimony for that, nothing will be better than that, and today's top pick of the DCVax-L JAMA Oncology paper by American Academy of Neurology Neurology Today Editorial Board as "The News That Mattered in 2022"? is again the testimony for that, yes nothing will be better than that!
Instead, the persistent empty, repetitive, useless, soulless chatter in message board and social media by those who claim they have never taken a position of any forms, and now a new crop of deniers coming on board all of a sudden with the same empty, repetitive, useless, soulless chatter as NWBO enters a new phase toward regulatory approvals is also the testimony for that, NWBO's success indeed has also drawn increasing attention from those deniers and manipulators.
Then, perhaps the only counter-argument sort of some substance is why the price is so low because all the empty, repetitive, useless, soulless chatter is just garbage in and garbage out, deserved nothing of consideration.
As the awareness picks up while the effect of lawsuit on the manipulators continually settles in, and most importantly as this phase of regulatory approvals moves forward to a certain point, the nerve of the deniers and manipulators will break. Then, the price will go up where it deserves.
Besides making money or living, how to do it is also important for a conscious human being, often a difference between humans and animals.
You don't get the point. I am talking about a competent person who can persuade major media outlets, even the FOX,which in your word with some truth though had been taken advantage of, to come onboard reporting the breakthrough results of Northwest Bio.
The person would present them the JAMA Oncology paper;
Would precisely explain how pseudo-progression changes the primary endpoint from PFS to OS, as a result it prolongs the trial duration;
Also because of the FDA's mandate for crossover, SAP must be revised and ECA would be used in comparison;
The trial results are indeed as JAMA Oncology reported positive with clinically meaningful and statistically significant results for nGBM, a significant improvement for 17 years, and for rGBM, an even more significant improvement for over 20 years; and
The implication of the positive trial results now for GBM is broad and huge for the vaccine can potentially be used to treat all solid tumors, and can be an essential part of cure for many cancers in combination.
After that I think the media would understand better Northwest Bio's stance, and I don't think even FOX would feel it would loss face if it follows up and reports the final results of the trial it reported before. And some of them may feel if not report now, it would miss out truly a breaking news with huge positive implication for years to come.
At the time, Northwest Bio was still a Nasdaq traded company. And Les was saying the vaccine would be available in late 2014. LOL
I guess part of the reason FOX has not followed up as promised is Northwest Bio's huge miss on its timeline.
But we all know the story why, and I think if the Northwest Bio has somebody competent enough, it should not be very difficult to explain why.
why PFS > OS
As a result the trial takes longer than anticipated.
You may be right the major cable channels won't touch a stock on the OTC, but the channels can of course report on major medical and biotech breaking news. They can and should report major advances in clinical trials and potential new treatments which have the potentials to save lives regardless what company which hold the news!
It's just a matter of who can do that job, contacting and persuading the media if they don't report the news, they are missing out a major breaking news.
That means they may not have interests or may be prohibit to reporting an OTC company but they should be able to report substance news. It will be no taboo for them to report the results of the Phase 3 clinical trial using DCVax-L (Murcidencel) vaccine to treat GBM patients.
The problem is does Northwest Bio have the right advocating firm/person to do that kind of job? From the history, Northwest Bio seems to have never had that kind of record. Can this time be different with the positive news and JAMA publication?
Personally, I think it is coming!
28k shares more this morning so far, steadily averaged up my base. People want to buy high at assuring time such as with good news, not me. I like to buy at pessimistic times.
Look at the huge payday ahead, not a problem for me, either it's months, days or year.
MIA, BLAs to multiple RAs, deals of any kind but substantial, market awareness picking up, VIPs with big $ onboard, RA approval.
Dynamic of current pessimism can change anytime with news either expected or unexpected.
For a long time, I have advocated for no transparency or minimal transparency allowed by the law. I don't care about temporary "darkness" but I do care to get shorts burned while making multiple millions of profit.
Added 30k shares today at $0.729 to average up my cost base. Never pay attention to day to day price move except when I want to buy shares. Even with well over 7-figure of shares I am holding, no intention to trade a single share despite knowing MIA is imminent, when it happens price would be up, and BLA submissions to multiple RAs soon follow, again price would be up. Look at the first RA approval in 6-8 months.
If price continue to be at this low or lower, intended to buy more to average up. The general market sucks which puts pressure on our price, but this stock needs only a single big positive thing to say bye bye to low price.
Increased awareness, a solid institution taking a significant slice, regulatory news, lawsuit yielding material news, hints of big P knocking the door, ...
Then it will change all trading dynamic and find a strong support!
Yes indeed, I have more example attached later one in the same post which shows it can happen either days apart or at the same day, or just one day apart. Done my digging, I think it's enough.
More examples:
UK MIA 20075 ACCORD HEALTHCARE LIMITED ACCORD HEALTHCARE LIMITED, GROUND FLOOR, SAGE HOUSE, 319 PINNER ROAD, HARROW, HA1 4HF, UNITED KINGDOM ACCORD HEALTHCARE LIMITED, EDGEFIELD AVENUE, NEWCASTLE UPON TYNE, NE3 3NB, UNITED KINGDOM
Human 25/11/2022
UK MIA(IMP) 20075 ACCORD HEALTHCARE LIMITED ACCORD HEALTHCARE LIMITED, GROUND FLOOR, SAGE HOUSE, 319 PINNER ROAD, HARROW, HA1 4HF, UNITED KINGDOM ACCORD HEALTHCARE LIMITED, EDGEFIELD AVENUE, NEWCASTLE UPON TYNE, NE3 3NB, UNITED KINGDOM
Investigational 25/11/2022
This one days apart:
UK MIA(IMP) 19054 ALIUM MEDICAL LIMITED ALIUM MEDICAL LIMITED, UNIT 7, CAPITAL BUSINESS PARK, MANOR WAY, BOREHAMWOOD, WD6 1GW, UNITED KINGDOM Investigational 13/07/2022
UK MIA(IMP) 17087 ALLERGY THERAPEUTICS (UK) LIMITED ALLERGY THERAPEUTICS (UK) LIMITED, DOMINION WAY, WORTHING, BN14 8SA, UNITED KINGDOM ALLERGY THERAPEUTICS 2, UNIT A/B, DOMINION WAY, WORTHING, BN14 8NW, UNITED KINGDOM
Investigational 29/09/2022
UK MIA 17087 ALLERGY THERAPEUTICS (UK) LIMITED ALLERGY THERAPEUTICS 2, UNIT A/B, DOMINION WAY, WORTHING, BN14 8NW, UNITED KINGDOM ALLERGY THERAPEUTICS (UK) LIMITED, DOMINION WAY, WORTHING, BN14 8SA, UNITED KINGDOM
Human 06/10/2022
the one below, one day apart:
UK MIA(IMP) 22443 ALLIANCE MEDICAL RADIOPHARMACY LIMITED ALLIANCE MEDICAL RADIOPHARMACY LIMITED , ROYAL MARSDEN HOSPITAL, DOWNS ROAD, SUTTON, SM2 5PT, UNITED KINGDOM
Investigational 11/07/2022
UK MIA 22443 ALLIANCE MEDICAL RADIOPHARMACY LIMITED ALLIANCE MEDICAL RADIOPHARMACY LIMITED , KEELE UNIVERSITY SCIENCE PARK, KEELE, ST5 5BX, UNITED KINGDOM ALLIANCE MEDICAL RADIOPHARMACY LIMITED , ROYAL PRESTON HOSPITAL, SHAROE GREEN LANE, FULWOOD, PRESTON, PR2 9HT, UNITED KINGDOM ALLIANCE MEDICAL RADIOPHARMACY LIMITED , ROYAL MARSDEN HOSPITAL, DOWNS ROAD, SUTTON, SM2 5PT, UNITED KINGDOM
ALLIANCE MEDICAL RADIOPHARMACY LIMITED, UNIT 19, QUADRUM PARK, OLD PORTSMOUTH ROAD, PEASMARSH, GUILDFORD, GU3 1LU, UNITED KINGDOM
ALLIANCE MEDICAL RADIOPHARMACY LIMITED, NOBEL WAY, DINNINGTON, SHEFFIELD, S25 3QB, UNITED KINGDOM
Human 12/07/2022
And most interesting thing, as I have suspected for NWBO as well, MIA(IMP) and MIA can be issued on the same day (an example below) or days apart (I have suspected we will have MIA issued in days):
UK MIA(IMP) 50506 RECIPHARM HC LIMITED RECIPHARM HC LIMITED, LONDON ROAD, HOLMES CHAPEL, CREWE, CW4 8BE, UNITED KINGDOM
Investigational 24/12/2021
UK MIA 50506 RECIPHARM HC LIMITED RECIPHARM HC LIMITED, LONDON ROAD, HOLMES CHAPEL, CREWE, CW4 8BE, UNITED KINGDOM
Human 24/12/2021
It is definitely not the same thing or just an extension of the previously issued authorization (https://www.otcmarkets.com/stock/NWBO/news/Northwest-Biotherapeutics-Announces-Filing-of-Application-for-License-for-Commercial-Manufacturing-at-Sawston-UK-Facilit?id=363861)
December last year's pr: "The second and third licenses were received in December, 2021, from MHRA, and provided authorization for manufacturing cellular therapies for use in clinical trials and compassionate use ("Specials") cases, respectively."
My guess is it's the real deal, even if not the final issuance, but it signifies all parts have been inspected and all outstanding items have been resolved.
So maybe this is it or a final issuance may be just days away. We will know something definite tomorrow as many investors have contacted the company for clarification.
Definitely tomorrow morning .
At this stage without any approved products such as approved DCVax-L, it's of course on the legal basis of INVESTIGATIONAL (clinical trials), ie MIA (IMP). The significance for this is that all parts have been checked ok for finally commercial manufacturing authorization issuance pending product approval.
Once after MHRA reviews BLA, the MIA (IMP) wold change to MIA on the legal basis of HUMAN.
So IMO this is what we should get at this stage, and it's as significant as a commercial manufacturing license pending approval of a manufacturing product.
The authorization for investigational manufacturing had been issued last year on 21 December: https://nwbio.com/northwest-biotherapeutics-announces-mhra-approval-of-license-for-gmp-manufacturing-at-sawston-uk-facility/
No need for MHRA to authorize the same thing twice, although with different forms.
Nobody would be trustworthy posting in a bb of forecasting materially significant news with dumb confidence. It's elementary reasoning. Of course sometimes a dead clock is right twice a day.
Dr. Brem's rebukes to AF's ignorant tweet re early state $MRNA $MRK combo trial:
Contrast today’s $MRNA $MRK encouraging mRNA neoantigen cancer vax news with the futility of the $NWBO “dumb” dendritic cell technology. I don’t expect $NWBO ‘s odious, online mob to understand why they’re being sold bupkis. pic.twitter.com/n9abXqDmDi
— Adam Feuerstein ✡️ (@adamfeuerstein) December 13, 2022
Preemptively bought 30k shares more this morning. The reason is because I knew someone would ploy manipulation based on mrna+merck early stage combo trial + AF's dumb tweet. My response besides the above, here
$NWBO $XBI @adamfeuerstein talking about early stage data not peer reviewed. for an already immune compromised patient,not enough cells to use even immune response triggered; deadly cytokine storm, a treatment no one can afford. DCVax overcomes all above shortcoming! pic.twitter.com/FNb2vjYPP4
— Arh Dan (@Arhdan9) December 13, 2022
Just bought 15k more at around 0.84, since I bought i went up and {ok it down a bit at 9:45, I shall do more then}. If we all buy some, $1 is just some keys away.
As I said too many traders, pawns of MMs, short hedges in this board. So this is my last post, and I am back to my holidays on this board.
Agree. on the other hand, this stock has too many traders in addition to committed shorts, MMs, AF, etc., but lack of committed longs, particularly the big ones. the few hedges with positions are either not big enough or not committed, so basically they don't count in my calculation.
This has continually presented a hugely undervalued price for those who aim big future return.
As I am typing this, the price looks very attractive for me. I am going to back to hit buy key.
GL
Approvals are in the card, nothing has changed. Even old school Stupp agrees (he doesn't imply he disagree anyway). Anyone who may question like Stupp whether efficacy of DCVax-L for nGBM is derived from biases or some kind of accident, or something else but DCVax-L, just ask this simple question: if the efficacy not from DCVax-L, why the same DCVax-L in the same trial for the same patient population has produced this resounding, hugely positive OS improvement for rGBM patients?
It would be an elementary reasoning, and the conclusion is yes the efficacy seen for nGBM in the trial is indeed from DCVax-L, and it's impossible from anything other that!
Added 30k shares yesterday to my well over 7-figure existing shares after carefully comprehend Stupp's commantary. I don't know how price will be today or on the days ahead, I do know it's vastly undervalued in the long run. Intended to buy more when price is still in such ranges.
Soft bash commentary wrangling on some already well-explained yet understandably not perfect issues. Considering the high stake of DCVax platform when approved on his "enterprise" Stupp protocol and TT Fields (Tumor Treating Fields), yes he intended to ignore/downplay the pristine safety profile and the efficacy evidence resulted from unprecedented efficacy on rGBM patients. I bought 30k shares more today after a while of hesitation after reading his commentary.
BTW, below is my email to him sent this morning:
On your commentary titled "2022 Top Story in Oncology: DCVax in Patients With Newly Diagnosed and Recurrent Glioblastoma"
Yahoo/Sent
Xxx xxx@yahoo.com>
To:roger.stupp@northwestern.edu
Thu, Dec 8 at 1:22 p.m.
Dear Dr. Stupp,
Well first thank you very much for your significant, unmatched contribution to GBM treatment and management over the past decades. Do you think what is important and significant in terms of DCVax-L treatment for GBM patients, besides what you having reasoned and questioned, is its benign safety profile, the strong support of its efficacy from the trial results obtained for rGBM patients? Your suggestion for its full potential with other approved agents in combination is duly appreciated.
Looking forward to your reply,
Sincerely,
xxx, PhD
I inquired and was also offered C shares; then my wife came up with a better idea: since our family has already owned too many shares, and the C shares we planned to buy would still be a small faction so our decision was instead to buy in the open market taking the advantage of low share price (250k shares bought so far).
The reason is that by buying in the open market we hoped the next offered price for C shares would be higher than the previous offering of roughly about $0.62 per share ($15-16/25). We hate to see share price constantly got negative impact with each offering, which has happened previously.
The more investors buy shares from open market the chance is higher the next offering would be at higher price.
The above is exactly the reason I told Les about our decision.